Molecular Diagnostics Company: Exact Sciences Corp (EXAS) (1995)

Exact Sciences Corporation (NASDAQ:EXAS) was founded in 1995 and is headquartered in Madison, Wisconsin, with 677 full-time employees. It is a molecular diagnostic company that focuses on non-invasive colorectal cancer screening.

Exact Sciences CorporationEXAS Logo

Exact Sciences Corporation (EXAS):

Exact Sciences Corporation is a molecular diagnostic company focused on the development of non-invasive colorectal cancer screening products. Cologuard, developed by Precision Science, is a non-invasive, fecal DNA-based colorectal cancer screening test for detecting pre-cancerous lesions or polyps, and the four stages of colorectal cancer.

The Cologuard test covers: the cells peeled off from the feces from the colon every day, the exclusive and patented method for isolating and studying human DNA; and the detection of blood in feces with protein markers, which is an antibody-based immunochemical stool test.

Precision Science’s stool-based DNA colorectal cancer screening technology also focuses on inflammatory bowel disease (IBD).

In addition, Precision Science Corporation signed a joint research, authorization and procurement agreement with Genzyme Corporation (formerly NASDAQ:GENZ), and developed tests with the Mayo Foundation for medical education and research to detect other gastric cancers, major esophagus and pancreas Dirty cancer, etc.

Notify of
Inline Feedbacks
View all Intels

Chinese stocks: Tianyin Pharmaceutical (TPI) (1994)

Plastic film and aluminum alloy company: Tredegar Corp (TG) (1989)